Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling therapies for asthma and COPD. Although other nonsubstitutable salmeterol/fluticasone propionate inhalers were recently introduced to the market (e.g., Teva’s AirDuo and its generic), their uptake has not been very robust. This Asthma and COPD Emerging Therapies series tracks the awareness, trial, and use of Wixela Inhub by U.S. physicians at one, six, and twelve months after its launch—data that should give Mylan and its competitors insight into the product’s market uptake. The series also examines physician-anticipated trends in asthma and COPD treatment, particularly with respect to the uptake of Wixela Inhub, and assesses Mylan’s promotional efforts.

QUESTIONS ANSWERED

  • What are U.S. physicians’ awareness of, familiarity with, and perceptions related to Wixela Inhub?
  • Among prescribers of Wixela Inhub, to which patients are they prescribing it, what are the reasons for prescribing it, and how satisfied are they with Wixela Inhub?
  • How do prescribers and nonprescribers compare across key metrics?
  • How are the trial and adoption of Wixela Inhub tracking compared with other recent products for asthma and COPD?

Geography : United States

Primary Research : Survey of approximately 75 U.S. physicians for each wave

Key metrics included :

  • Unaided and aided awareness of Wixela Inhub
  • Familiarity with and impressions of Wixela Inhub
  • Prescriber and nonprescriber profiles
  • Willingness to prescribe Wixela Inhub
  • Performance of Wixela Inhub on key attributes
  • Sales representative visit frequency, reach, and effectiveness
  • Benchmarking against previously launched agents

PRODUCT DESCRIPTION

Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.

Table of contents

  • Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)
    • Asthma and COPD Emerging Therapies Salmeterol / Fluticasone Generic US Wave 2 (October 2019)

Author(s): Ajay Puri, MBA

Ajay Puri is a Research Associate on the Immune and Inflammatory team at Decision Resources Group. He currently focuses on Inflammatory bowel disease (IBD). He holds a bachelor’s degree in Pharmacy and has earned his MBA in Pharmaceutical marketing from NIPER, Mohali. Prior to joining DRG, Ajay worked as a Business Research Associate (Oncology) at ZS Associates. He has worked on multiple client projects revolving around competitive intelligence, opportunity assessment, trend analysis, clinical trial analysis, and product/company profiling.  


Related Reports

Chronic Obstructive Pulmonary Disease | Emerging Therapies | Asthma & COPD | Salmeterol & Fluticasone Generic Wave 2 (US)

Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling the...

View Details

Asthma | Landscape & Forecast | Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

View Details

Asthma | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS F...

View Details

Asthma | Emerging Therapies | Dupixent (Dupilumab) (US) Wave 2

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatmen...

View Details